Wer hat Infos zu Geltex - 500 Beiträge pro Seite

[info-paket]

Wer hat Infos und Kursziel für Geltex

[info-paket]

wie ich sehe hat keiner infos zu geltex, oder habt ihr meinen Artikel vergessen

[Blomquist]

Probier mal hier zu finden was Du suchst:

http://finance.yahoo.com/q?s=GELX&d=t

http://www.geltex.com

[hgw]

Weiß jemand warum Geltex im Moment am steigen ist?

Über neue Infos würde ich mich freuen

hgw

[elrigo]

Hallo hgw
Ich vermute dass jetzt ein neues Mittel auf den Markt kommt. Hier ein Auszug aus einem anderen von mir verfassten Thread. Wichtiger ist jedoch ein Mittel gegen zu hohen Cholesteringehalt das wahrscheinlich in den nächsten Wochen auf den Markt gelangen dürfte. Das ColestraGel wird dann von 2 starken
Partnern WARNER LAMBERT und dem japanischen PHARMARIESEN SANKYO vertrieben. (viele die nur Mc Donald`s kennen sind die zukünftigen Kunden)
Dies bedeutet dass Geltex bereits im Jahr 2001 Gewinne erwirtschaften wird.

Desweiteren ist aus Charttechnischer Sicht vestzustellen, daß Geltex schon seit ca. 3 Monaten besser als der Markt läuft und heute sogar sein Jahreshoch durchbrochen hat. Ich bin weiter sehr optimistisch bei Geltex


Gruß elrigo

[gholzbauer]

Geltex gerade neues 52-W-Hoch 26 9/16 $,
war aber nicht schwierig, von März bis jetzt andere Biotechs outzuperformen, da GELX vorher nicht besonders gut lief und wohl deswegen nicht so stark korrigierte, von Allzeithochs (40 $ oder so) sind wir noch weit weg.

Genzyme, GelTex Announce FDA Approval to Market Renagel Tablets New Dosage Form Offers Additional Tools for Managing Phosphorus Levels
CAMBRIDGE and WALTHAM, Mass., Jul 13, 2000 /PRNewswire via COMTEX/ -- Genzyme General (Nasdaq: GENZ chart, msgs) and GelTex Pharmaceuticals Inc. (Nasdaq: GELX chart, msgs) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Renagel(R) Tablets (sevelamer hydrochloride) in 800 mg and 400 mg dosages for the reduction of serum phosphorus in hemodialysis patients with end-stage renal disease.

Renagel is currently available in a 403 mg capsule form. The new tablet formulation of Renagel will provide physicians with two new dosing options to more easily manage patients into the normal serum phosphorus range. The 400 mg tablet is much smaller than the current capsule, while the 800 mg tablet can be used by physicians to manage patients who may need higher dosages but have been reluctant to take the required number of pills.

"The introduction of Renagel Capsules twenty months ago represented a significant advance in the control of serum phosphorus for the dialysis patient population," said Christi van Heek, president of Genzyme General`s therapeutics business. "The introduction of a new tablet formulation of Renagel continues Genzyme`s commitment to improving the treatment of end-stage renal disease."

Mark Skaletsky, chairman and chief executive officer of GelTex Pharmaceuticals, said: "We are pleased to be able to bring this new form of our effective phosphate binder to physicians to help their dialysis patients. We expect a rapid adoption of these tablets when they become available to physicians later this year."

Patients on dialysis are at high risk of having dangerously elevated phosphorus and calcium levels. If left untreated, elevated blood phosphorus levels can lead to a number of serious conditions, including cardiac and other soft tissue calcifications, renal bone disease, and death.

Renagel, marketed by Genzyme under a joint venture with GelTex, is designed to bind and remove dietary phosphorus in the gastrointestinal tract and eliminate phosphorus through normal digestive processes. One of the major benefits of Renagel is that it does not contain calcium.

The number of patients undergoing dialysis for end-stage renal disease is estimated to be 280,000 in the United States and 170,000 in Europe. These numbers are increasing by 7-8 percent annually.

Renagel was introduced in the United States in late 1998, and is also available in Europe, Canada, and Israel. Genzyme filed for European marketing approval of Renagel Tablets during the first quarter of this year and expects to file in Canada during the third quarter of this year.

Renagel is indicated for the reduction of serum phosphorus in patients with end-stage renal disease on hemodialysis. Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction. The drug should be used with caution in patients with swallowing or severe gastrointestinal motility disorders or major GI surgery. In a placebo-controlled study, adverse events were similar to placebo. The most common treatment-emergent adverse events in a Phase 3 crossover study were not dose related and included diarrhea, infection, and pain.

See attached package insert for full prescribing information for Renagel Tablets.

Genzyme General develops and markets therapeutic products and diagnostic products and services. Genzyme General has three therapeutics products on the market and a strong pipeline of products in development focused on the treatment of genetic disorders. Genzyme General is a division of the biotechnology company Genzyme Corporation.

GelTex develops and markets non-absorbed polymer drugs that bind and eliminate targeted substances within the gastrointestinal tract. In addition, GelTex is developing small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators. Therapeutic areas of interest include hyperphosphatemia, hypercholesterolemia, cancer, iron overload and infectious diseases.

This press release contains forward-looking statements, including statements about the anticipated rate of adoption of Renagel Tablets, the expected timing of market introduction of Renagel Tablets, the estimated end-stage renal disease patient population, and the estimated growth rate of that patient population. Actual results may materially differ due to numerous factors, including without limitation market acceptance of Renagel Tablets, decisions by regulatory authorities, availability of reimbursement from third- party payers, the accuracy of the companies` information about the end-stage renal disease patient population, and the risks and uncertainties described in Genzyme Corporation`s reports filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation Exhibit 99.2 to Genzyme`s Annual Report on Form 10-K for the year ended December 31, 1999, as amended.

[gholzbauer]

28$, +7%, völlig gegen den gestrigen Biotech-Trend.

[gholzbauer]

Ich frage mich, wieso das Ergebnis über den Erwartungen liegt. Das 20-Mio.-$-milestone-payment war doch bekannt (etwa nicht?), und die Kosten sind ungefähr gleich geblieben, war auch zu erwarten. Pennen die Analysten?


GelTex Pharmaceuticals Reports Second Quarter 2000 Results; Phase 1 Initiated for a Non-Absorbed Toxin Binding Polymer
WALTHAM, Mass., Jul 18, 2000 /PRNewswire via COMTEX/ -- GelTex Pharmaceuticals, Inc. (Nasdaq: GELX chart, msgs) today reported its financial results for the quarter ended June 30, 2000. For the three-month period, GelTex reported net income of $16.3 million, or $0.79 per diluted share, on revenues of $24.2 million, operating expenses of $10.1 million, and income from equity in the Renagel Joint Venture of $0.8 million. In the comparable quarter in 1999, the Company had a net loss of $9.4 million, or ($0.56) per share, on revenues of $1.1 million, operating expenses of $9.7 million and loss from equity in the Renagel Joint Venture of $1.8 million. The financial results for the second quarter primarily reflect a non-recurring $20.0 million milestone payment earned by the Company upon the receipt of marketing approval for Welchol(TM) by the U.S. Food and Drug Administration (FDA). This milestone was offset by continuing costs associated with regulatory support, clinical trials, and manufacturing support of Renagel(R) and Welchol(TM), as well as costs associated with the Company`s other research and development programs. The $24.2 million in revenue earned in the second quarter includes the $20.0 million milestone, as well as $4.2 million of reimbursement revenue earned under the Company`s collaborative agreements for Renagel(R), Welchol(TM), and its second-generation lipid-altering compound. GelTex had $119 million in cash and cash equivalents at June 30, 2000.

For the six-month period ended June 30, 2000, revenues totaled $31.7 million and expenses were $20.4 million, resulting in net income of $13.0 million, or $.66 per diluted share. In the comparable six-month period in 1999, there was a net loss of $17.1 million, or ($1.02) per share, on revenues of $4.7 million and expenses of $20.0 million. The financial results for the six-month period primarily reflect the $20.0 million non-recurring milestone payment and $8.7 million in reimbursement revenue offset by costs associated with Renagel(R), Welchol(TM), and other research and development programs.

Net sales of Renagel(R) for the second quarter of 2000 were $10.2 million which represents a 27.5% increase over the first quarter`s net sales of $8.0 million. Total retail prescriptions for the second quarter increased 18% to 57,007, while new prescriptions rose by 19% to 24,448.

In addition, on June 2, 2000, GelTex filed an Investigational New Drug (IND) application with the FDA for a non-absorbed toxin binding polymer, GT160-246, for the treatment and prevention of Clostridium difficile (C. difficile) colitis. C. difficile is the most common cause of antibiotic-associated diarrhea and is a significant problem in hospitals and extended care facilities, affecting at least 500,000 patients per year in the United States. Under normal conditions, the bacterial flora of the gastrointestinal tract prevent the growth of C. difficile. However, in hospitalized patients, antibiotics that are used to treat unrelated infections alter the normal intestinal flora, allowing the proliferation of C. difficile. C. difficile releases two toxins, Toxin A and Toxin B, that are the essential virulence factors in this bacterial infection. The clinical symptoms of the infection range from diarrhea to severe colitis (inflammation of the large intestine).

C. difficile infection is currently treated with antibiotics. However, 25% of patients treated with antibiotics relapse or do not respond to therapy. This relapse rate and concern over emerging antibiotic resistance have created a need for new therapies to treat this disease. We have identified a new antibiotic polymer that has exhibited promising activity in neutralizing the toxins and preventing disease in animal models. We believe this presents a novel approach for the management and prevention of hospital-associated C. difficile colitis.

GelTex received clearance from the FDA to begin testing of GT160-246 in humans. A Phase 1 trial of GT160-246 has begun.

"This quarter has been the most exciting period of time for everyone associated with GelTex since the founding of the Company," commented Mark Skaletsky, President and Chief Executive Officer of GelTex. "Most significantly, we received FDA approval of Welchol(TM), our second product taken from discovery through approval. Secondly, with the filing of our IND for GT160-246, we have advanced another compound into clinical trials. Additionally, Renagel sales momentum continues with $10.2 million in sales for the second quarter of 2000. These events have been followed up by the FDA approval to market Renagel(R) Tablets."

GelTex develops and markets non-absorbed polymer drugs that bind and eliminate targeted substances within the gastrointestinal tract. In addition, GelTex is developing small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators. Therapeutic areas of interest include hyperphosphatemia, hypercholesterolemia, cancer, iron overload and infectious diseases. GelTex`s releases are available at http://www.geltex.com

This press release contains forward-looking statements, including statements concerning the Company`s plans relative to GT160-246, a toxin binder for C. difficile, as well as sales growth for Renagel. Actual results may materially differ due to numerous factors, including the results of future clinical trials for GT160-24, sales growth for Renagel(R), market acceptance for Welchol(TM), as well as the risks and uncertainties described in the Company`s reports filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended.

Condensed consolidated statements of operations and balance sheets for the Company are attached.


GelTex Pharmaceuticals, Inc.
Condensed Consolidated Income Statements
(Unaudited)

Three Months Ended Six Months Ended
June 30, June 30,
2000 1999 2000 1999

Revenues
Collaborative Joint
Venture project
reimbursement $1,098,000 $1,079,000 $2,441,000 $2,962,000
Contract Revenue 23,064,000 -- 29,304,000 1,752,000
Total Revenue 24,162,000 1,079,000 31,745,000 4,714,000

Costs and expenses
Research and
development 7,244,000 7,275,000 14,645,000 14,420,000
Collaborative Joint
Venture project
costs 1,098,000 1,079,000 2,441,000 2,962,000
Total research
and development 8,342,000 8,354,000 17,086,000 17,382,000

General and
administrative 1,769,000 1,392,000 3,348,000 2,605,000
Total costs and
expenses 10,111,000 9,746,000 20,434,000 19,987,000

Income (loss)
from operations 14,051,000 (8,667,000) 11,311,000 (15,273,000)

Interest income,

net 1,401,000 1,040,000 2,326,000 2,188,000

Equity in

loss of

Renagel Joint

Venture 811,000 (1,789,000) (604,000) (4,068,000)

Net income

(loss) $16,263,000 $(9,416,000) $13,033,000 $(17,153,000)


Basic net
income (loss)
per share $0.81 $(0.56) $0.67 $(1.02)
Shares used
in computing
basic net
income (loss)
per share 20,141,000 16,854,000 19,331,000 16,854,000

Diluted net
income (loss)
per share $0.79 $(0.56) $0.66 $(1.02)
Shares used in
computing diluted
net income (loss)
per share 20,569,000 16,854,000 19,753,000 16,854,000


Condensed Balance Sheet
(Unaudited)
June 30, December 31,
2000 1999

Cash, cash equivalents
and marketable securities $119,087,000 $72,429,000
Other current assets 5,228,000 2,839,000
Total current assets 124,315,000 75,268,000
Property and equipment, net 13,847,000 11,118,000
Other assets 25,102,000 19,703,000
Total assets $163,264,000 $106,089,000
Current liabilities $5,008,000 $6,822,000
Long-term obligations 6,412,000 6,565,000
Stockholders` equity 151,844,000 92,702,000
Total liabilities and
stockholders` equity $163,264,000 $106,089,000
Source: GelTex Pharmaceuticals, Inc.

[gholzbauer]

Schade, dass beim einfachen Kopieren die Tabellen zerstört werden. Gibt es einen Trick, der das verhindert?

[gholzbauer]

GELX bei 37 3/4 $.
Der einzige Biotechwert, der mir z.Z. Freude macht.
ARIA,SEPR,CVTX,CRIS @&?*#!!!!!
gholzbauer

[banan]

Geltex Pharma.


GelTex-Wissenschaftler erhalten Preis

Wie GelTex Pharmaceuticals, Inc. (Nasdaq: GELX, WKN: 898062) heute bekanntgab, haben die beiden Wissenschaftler Dr. W. Harry Mandeville und Dr. S. Randall Holmes-Farley die Auszeichnung der American Chemical Society erhalten.
Die Auszeichnung wurde in Anerkennung ihrer Leistungen bei der Entedeckung neuer therapeutischer Wirkstoffe vergeben. Die aktuellen Produkte wurden unter Einbeziehung der Polymer-Chemie entwickelt:
Sevelamer hydrochloride ist ein Medikament für die Behandlung von Patienten, die unter Nierenerkrankungen leiden und sich der Hämodialyse unterziehen müssen. Es wird unter dem Namen Renagel® vertrieben.
Colesevelam hydrochloride soll zur Senkung des Cholesterin-Spiegel eingesetzt werden und erhielt das O.K. der FDA im Mai 2000. Das Medikament wurde unter dem Namen WelChol™ an Sankyo Pharma Inc. lizenziert.

24.08.00 15:00 -hb-



Nur ´ne kleine Info

[info-paket]

Geltex hat gestern die Marke von 40 USD geknackt. Seht euch mal den schönen Chart an.
Weis leider nicht wie man ihn hier einstellt.

[RAIBACMGI]

Hallo info-paket,

habe mal wieder was besonderes für Dich (und die anderen):
OS auf Vertex: 721124 - die ersten 100% gehören schon mir
außerdem Pictet Biotechfond : 988562
und ganz spekulativ OS auf MOT: 595178

tschau

[RAIBACMGI]

...und noch was - bei uns im Betrieb sind letzte Woche 2MA geflogen, weil sie im Geschäft private Mails verschickt haben - war zwar auch in der Mittagspause so wie bei Dir, aber hat nichts genützt.

tschau

[gholzbauer]

Hier ein 5-Jahres-Chart:
http://www.siliconinvestor.com/research/chart.gsp?&s=GELX&ti…

Andere Chart-Zeiträume anklickbar.

[gholzbauer]

Genzyme General to buy GelTex in nearly $1 billion deal
CAMBRIDGE, Mass., Sept 11 (Reuters) - Biotechnology company Genzyme General Corp. (NASDAQ: GENZ) on Monday said it has agreed to buy drug maker GelTex Pharmaceuticals Inc. (NASDAQ: GELX) in a cash-and-stock deal worth nearly $1 billion.

Under the deal, Cambridge-based Genzyme General obtains two GelTex drugs and a pipeline of "promising" potential products, it said. GelTex has two approved products -- Welchol, a newly approved cholesterol fighter, and Renagel, a dialysis medicine expected to earn as much as $43 million this year.

Genzyme already jointly markets Renagel with GelTex and said in the deal announcement that it now expects the product to drive its future growth and become a blockbuster within 10 years.

The deal, expected to close in the fourth quarter, calls for GelTex shareholders to receive 0.7272 of a share of Genzyme General common stock or $47.50 in cash for each GelTex share owned. That price reflects a 27 percent premium over GelTex`s closing share price of $37-3/8 on Friday. The total deal value will be roughly $1 billion, based on GelTex`s 21.4 million shares outstanding currently and Genzyme General`s closing share price of $65.3125 on Sept. 8.

Genzyme said that the GelTex purchase may result in a one-time charge in the fourth quarter of 2000, related to the write-off of in-process research and development. The combination, to be accounted for as a purchase, is expected to hurt Genzyme General`s near-term earnings but it predicted to boost them in 2002, before depreciation and amortization of good will.

[gholzbauer]

Genzyme General to Acquire GelTex Pharmaceuticals Sees Renagel(R) as Potential Blockbuster and Important Driver of Growth
CAMBRIDGE and WALTHAM, Mass., Sep 11, 2000 /PRNewswire via COMTEX/ -- Genzyme General (Nasdaq: GENZ chart, msgs) and GelTex Pharmaceuticals Inc. (Nasdaq: GELX chart, msgs) today announced that they have entered into a definitive merger agreement under which Genzyme will acquire GelTex. The transaction is expected to close in the fourth quarter, pending regulatory and GelTex shareholder approval.

With the acquisition, Genzyme General will obtain two patent-protected, marketed products-Renagel(R) (sevelamer hydrochloride) and WelChol(TM) (colesevelam hydrochloride) -- along with a significant pipeline of promising products and a proven and productive polymer technology platform. Renagel is a rapidly growing product used in the treatment of patients with end-stage renal disease undergoing dialysis. WelChol is a new cholesterol-lowering agent, which will be launched this month by Sankyo-Parke Davis.

Genzyme believes that the worldwide market opportunity for Renagel is far greater than originally anticipated, and believes that Renagel will transform clinical practice and outcomes. Genzyme expects that at least four fundamental factors will propel the product`s exponential growth: rapidly increasing market share driven by mounting evidence about the role of calcium in cardiovascular disease among dialysis patients; appropriate adjustment of daily doses of Renagel by physicians to lower patient phosphorus levels into the normal range; substantial growth in the dialysis patient population; and the potential for Renagel to lower the overall cost of caring for dialysis patients.

"We have concluded that Renagel has the potential to become a blockbuster product and that it will serve as an important driver of our future growth," said Henri A. Termeer, chairman and chief executive officer of Genzyme Corp. "We believe that Renagel represents the most important advance in the treatment of dialysis patients since the introduction of Epogen(R). We expect to soon begin a large clinical trial to study the product`s ability to improve morbidity and mortality. Genzyme expects that the market potential for Renagel will surpass $500 million within five years and that it will reach $1 billion within the decade. We have developed a very close relationship with the GelTex team through our successful partnership to bring Renagel to the market. We value them highly and look forward to a promising future together."

Mark Skaletsky, president and chief executive officer of GelTex, said: "Our merger with Genzyme will provide tremendous value to GelTex shareholders and employees. The combination of Genzyme`s resources and global commercial infrastructure with GelTex`s demonstrated ability to develop products, creates a very powerful company with an outstanding product pipeline. We are very proud of all that we have accomplished over the last eight years and look forward to joining with Genzyme to build a significant company that provides therapeutic products that improve human health."

Terms of the Agreement

Under the terms of the agreement, GelTex shareholders will receive 0.7272 of a share of Genzyme General common stock or $47.50 in cash for each GelTex share owned, subject to proration to maintain the cash portion of the consideration at 50 percent, approximately $500 million. The merger consideration represents a 27 percent premium over GelTex`s closing share price on September 8, 2000.

The tax-free transaction has a total value of approximately $1 billion, based on GelTex`s 21.4 million shares outstanding today and Genzyme General`s closing share price of $65.3125 on September 8.

The boards of directors of Genzyme Corp. and GelTex have approved the transaction, which is subject to clearance under the Hart-Scott-Rodino Anti-Trust Improvements Act. The transaction will require the approval of GelTex shareholders, and is subject to customary closing conditions.

Genzyme General expects that the acquisition of GelTex may result in a one-time charge in the fourth quarter of 2000, related to the write-off of in-process research and development. The acquisition, which will be accounted for as a purchase transaction, is expected to be dilutive to Genzyme General`s near-term earnings but is expected to become accretive to earnings in 2002 prior to depreciation and amortization of good will.

GelTex employs approximately 110 people. Genzyme plans to retain GelTex`s administrative offices and laboratories in Waltham, Massachusetts. In addition to its marketed products, its pipeline, and unique polymer technology, GelTex has assets that include approximately $119 million in cash, usable net operating loss tax carry forwards, important intellectual property protecting Renagel and their other products, and research facilities.

Renagel`s Potential Far Greater Than Initially Anticipated

Renagel`s growth will be driven by four key factors: rapidly increasing market share from its establishment as a preferred first-line treatment, dose adjustment by nephrologists to lower phosphorus levels into the normal range, substantial growth in the number of dialysis patients worldwide, and Renagel`s potential to lower the total cost of treating these patients.

Specifically, Genzyme expects that the fundamental change in clinician perspectives toward calcium-based binders will rapidly drive the growth of new prescriptions for Renagel, which is the only calcium-free, aluminum-free phosphate binder on the market. Currently, the majority of all dialysis patients are still on a calcium-based phosphate binder.

Within the last year, independent clinical evidence showing the relationship between elevated calcium intake and cardiovascular disease among dialysis patients has led to questions about the safety of calcium-based binders. Cardiovascular disease occurs at a markedly higher rate-and is the leading cause of death-in the dialysis population.

In response to this new clinical evidence, thought leaders within the nephrology community have begun to change the way dialysis patients are managed. According to Dr. Geoffrey A. Block, lead author of the landmark 1998 study correlating poor phosphorus management with mortality in dialysis patients: "The changing mindset of nephrologists across this country is based on both research and personal clinical experience. Too many of our patients die from heart disease, and now we recognize that our treatment of patients is inadvertently contributing to the problem. Leading experts on dialysis are recommending much lower levels of calcium intake. Renagel is the only FDA approved product on the market that lowers phosphorus without adding calcium. Renagel is therefore becoming the standard of care and first-line therapy for every single patient on dialysis."

To demonstrate Renagel`s ability to slow cardiac calcification, Genzyme is currently conducting a three-year study comparing the product with standard calcium binders. One-year results will be available during the first half of 2001.

This study is also designed to further study Renagel`s ability to lower phosphorous into the normal range. Renagel has shown that it can safely lower serum phosphorous levels into the normal range-a historically difficult challenge for nephrologists. Many physicians have begun to increase the dosage level of Renagel in their patients in order to achieve that goal. The launch of a new tablet formulation of Renagel this month will help nephrologists manage patients into the normal serum phosphorus range.

Renagel`s growth will also be driven by a substantial increase in the number of patients undergoing dialysis. Worldwide, approximately 1 million people are now on dialysis and the number is expected to reach 1.7 million by 2009, led by the increased incidence of diabetes, hypertension, and a growing elderly population. The current annual cost of Renagel therapy is approximately $1,000 per patient and is expected to double within the decade from a combination of prescription-driven dosage increases and compliance improvements. Based on market penetration estimates and the availability of reimbursement, Genzyme expects Renagel revenues to reach $500 million within five years and $1 billion in ten years.

Another major driver of Renagel`s growth will be its potential to improve patient morbidity and mortality. In a study to be published next month, Dr. Allan Collins of the University of Minnesota showed a significant improvement in morbidity and observed improved trends in mortality among Medicare patients treated with Renagel compared with patients treated with calcium binders. In this retrospective analysis of data from the U.S. Renal Data System, Collins found a statistically significant 50 percent reduction in hospitalization among Renagel patients compared to the calcium-treated patients. He also observed a 35 percent reduction in deaths among Renagel patients, although the small sample size studied did not allow Collins to confirm its statistical significance. Collins` data has been presented at the 1999 American Society for Nephrology meeting and the 2000 National Kidney Foundation meeting.

Genzyme is currently designing-and plans to begin early next year-a large, prospective, randomized, clinical trial designed to confirm the impact of Renagel on patient morbidity and mortality.

One of the more intriguing aspects of the Collins study was its analysis of patient Medicare payment histories. In this analysis, Collins found dramatic annual costs savings for patients treated with Renagel. These savings averaged more than $17,000 per patient annually based on decreased hospitalizations alone. Genzyme believes Renagel`s ability to lower the overall cost of care for dialysis patients will play a critical role in the product`s long-term growth.

Finally, an additional and significant attribute of Renagel is that it has been shown in clinical studies to dramatically lower LDL cholesterol while increasing HDL cholesterol.

Renagel Revenue Growth

Renagel has generated average quarter-to-quarter revenue growth of 25 percent since its introduction. Renagel sales in 1999-the product`s first full year on the market-were $19.5 million. For 2000, Renagel sales are expected to more than double, and Genzyme is now revising its revenue guidance upward, for the second time this year, to around $45 million. Renagel revenues are expected to double again in 2001 and-within five years-to exceed $500 million.

Renagel is currently marketed in the United States, Europe, Canada, and Israel under a 50/50 joint venture between Genzyme and GelTex. The product is being developed and will be commercialized in Japan and other Pacific Rim countries by Chugai Pharmaceuticals and Kirin Pharmaceuticals under agreements with GelTex.

Other Benefits of the Transaction

In addition to Renagel, Genzyme`s acquisition of GelTex will also give it access to WelChol, three products in clinical trials and three more product candidates potentially entering clinical trials next year.

Genzyme will receive royalties from sales of WelChol, which is being launched by Sankyo-Parke Davis this month. A Phase 2 clinical trial of a second-generation version of WelChol will be completed this quarter and additional clinical trials are planned.

GelTex also has a number of exciting products in its pipeline. Its leading product in development is a toxin binder known as GT160-246 for Clostridium difficile (C. difficile), which is a major cause of antibiotic associated colitis, a condition common in hospitals and nursing homes. C. difficile affects over 500,000 patients per year, resulting in prolonged hospital stays and increased costs, and is the cause of an estimated 5,000 deaths annually. A Phase 1 trial of GT160-246 in normal volunteers was completed in August, and a Phase 2 clinical trial of the product is expected to begin later this year.

In addition, GelTex has made significant progress in its research efforts toward discovery of a new class of fat-absorption inhibitors. GelTex has identified a family of polymers that inhibit pancreatic lipase, the key enzyme involved in fat digestion in the intestine. In pre-clinical studies, these compounds have shown they can inhibit lipase with a potency in the range of that of known inhibitors. They have also show that they can significantly inhibit fat absorption. GelTex has also identified polymers that bind fat and prevent the oily stool associated with lipase inhibition. Since these compounds are high-molecular-weight polymers, they are unlikely to be absorbed into the blood stream. Such compounds could potentially inhibit fat absorption without causing oily stool side effects associated with current therapy.

GelTex`s robust polymer technology platform has produced two approved products and several promising product candidates within a short six-year timespan. Genzyme expects that this technology will be a consistent and productive source of product candidates to feed its therapeutics pipeline. Polymer technology has wide ranging applications, and polymer-based products enjoy a relatively quick development pathway and have proven to be very safe. GelTex`s scientists are widely respected in the industry, and the company`s two most senior scientists recently received an award from the American Chemical Society for their innovative application of polymer technology to the development of therapeutic agents.

Genzyme General develops and markets therapeutic products and diagnostic products and services. Genzyme General has three therapeutic products on the market and a strong pipeline of products in development focused on the treatment of genetic disorders. Genzyme General is a division of the biotechnology company Genzyme Corporation.

GelTex develops and markets non-absorbed polymer drugs that bind and eliminate targeted substances within the gastrointestinal tract. In addition, GelTex is developing small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators.

This press release contains forward-looking statements, including statements about the consummation and anticipated timing of the merger, the potential market opportunity for Renagel, the expected drivers of growth for the market opportunity, the anticipated impact of Renagel on Genzyme`s future growth, the potential short and long-term revenues from Renagel, the expected benefits of the merger, the value of the merger consideration, the tax-free nature of the transaction, the anticipated impact of the acquisition on Genzyme`s earnings, cash-earnings-per-share, and development programs, Genzyme`s plans concerning the operation of GelTex`s business after the merger, estimates concerning the current and future dialysis patient population, the anticipated impact of Renagel on patient morbidity and mortality, the cost of care for patients, plans to launch a new tablet formulation of Renagel, the anticipated benefits of the tablet formulation, plans to announce trial data, plans to initiate clinical trials of Renagel, GT 160-246, and other product candidates, estimates concerning the C. Difficile Colitis patient population, expectations concerning GelTex`s product candidates and polymer technology platform. Actual results may materially differ due to numerous factors, including without limitation conditions in the financial markets relevant to the proposed merger, the receipt of regulatory and other approvals of the transaction, the operational integration associated with the transaction and other risks generally associated with such transactions, increasing market acceptance of Renagel, increasing doses of Renagel, market acceptance of Renagel tablets, the competitive environment for the dialysis market, the results of clinical trials, the efficacy and safety of products, enrollment rates for clinical trials, the content and timing of submissions to and decisions by regulatory authorities, the availability of reimbursement from third-party payers, the ability to manufacture sufficient quantities of product for development and commercialization activities, the accuracy of the companies` information about the dialysis and the C. Difficile Colitis patient populations and the market for Renagel, the accuracy of the companies` expectations about growth in the dialysis patient population, the ability of Genzyme to successfully commercialize products and the risks and uncertainties described in Genzyme and GelTex`s reports filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation Exhibit 99.2 to Genzyme`s Annual Report on Form 10-K for the year ended December 31, 1999, as amended. GENZ stock is a series of common stock of Genzyme Corporation. Therefore, holders of GENZ stock are subject to the risks and uncertainties described in the aforementioned reports.

This material is not a substitute for the prospectus/proxy statement Genzyme and GelTex will file with the Securities and Exchange Commission. Investors are urged to read that document because it will contain important information, including detailed risk factors. The proxy statement/prospectus and other documents filed by Genzyme and GelTex with the SEC will be available free of charge at the SEC`s website ( www.sec.gov ) and from Genzyme or GelTex.

GelTex, its directors, and certain of its executive officers may be considered participants in the solicitation of proxies in connection with the merger. Information concerning GelTex`s directors and executive officers can be found in the documents filed by GelTex with the SEC. Certain directors and executive officers of GelTex may have direct or indirect interests in the merger due to securities holdings, vesting of options, and rights to severance payments if their employment is terminated following the merger. In addition, directors and officers, after the merger, will be indemnified by Genzyme, and benefit from insurance coverage, for liabilities that may arise from their service as directors and officers of GelTex prior to the merger. Additional information regarding the participants in the solicitation will be contained in the proxy statement/prospectus.

There will be a conference call beginning at 9:00 a.m. EDT today to discuss this morning`s news announcement regarding Genzyme General`s proposed acquisition of GelTex Pharmaceuticals, Inc.

If you would like to participate in this call, please dial 212-346-0257 beginning at 8:45 a.m. EDT. A replay of this call will be available from 12:30 p.m. EDT on September 11 through 12:00 p.m. midnight on September 18 by calling 800-633-8284 in the U.S., or 619-812-6440 outside the U.S., reference confirmation #16318162.

A replay of this call will also be broadcast over the internet at 1:00 p.m. EDT today on Genzyme`s Web site: www.genzyme.com . The replay of the call will be available through midnight EDT September 25.

Genzyme`s releases are available on the World Wide Web at http://www.genzyme.com . They are also available from Genzyme`s fax-on-demand service at 1-800-436-1443 within the United States or 1-201-521-1080 outside the United States.

GelTex`s press releases are available at http://www.geltex.com .



Source: Genzyme General

[banan]

Genzyme kauft Geltex



Das Biotechnologieunternehmen Genzyme (Nasdaq: GENZ) wird Geltex Pharmaceuticals (Nasdaq: GELX) für circa eine 1 Mrd. Dollar übernehmen. Der Übernahmevereinbarung zufolge wird Genzyme den Geltex-Aktionären 500 Mio. Dollar in bar und 7,8 Mio. Anteile an Genzyme geben. Der Hauptgrund für die Übernahme von Geltex dürfte wohl Renagel, ein Nierenmedikament, sein.



Renagel wird bei Nierenpatienten, die sich einer Dialyse unterziehen, eingesetzt. Es wird erwartet, dass es bis zum Ende des Jahrzehnts einen jährlichen Umsatz von 1 Mrd. Dollar erzielt. Im letzten Jahr, dem ersten vollen Produktjahr von Renagel, erreichte es einen Umsatz von 19,5 Mio. Dollar. Diese Zahl wird sich nach Meinung von Genzyme in den nächsten Jahren jährlich verdoppeln.



Das Genzyme-Papier wird von der Börse abgestraft und verliert aktuell 9,3 Prozent auf 59-1/4 US-Dollar.



Die Geltex-Aktie explodiert förmlich und steigt 16,9 Prozent auf 43-11/16 US-Dollar.


18:49 11.09, Gregor Miroslawski

[gholzbauer]

Hallo Geltex-Aktionäre,
welches Angebot nehmt ihr an? Oder verkauft ihr jetzt am Markt?
Ich denke, ich werde meine Genzyme-Position aufstocken, indem ich das Umtauschangebot annehme. Natürlich nur, solange GENZ nicht deutlich unter 1/0,7272x47,5$ bleibt.
Wie wird ein derartiger Umtausch vom Steuerrecht gesehen? Für die erhaltenen Genzyme-Aktien fängt die Spekulationsfrist doch nicht etwa neu an, oder? Bei GELX ist sie für mich gerade abgelaufen.
MfG,
gholzbauer

[kostolanys erben]

Liebe Geltexler,

nachdem wir nun über ein Jahr auf einer satten Portion geltexanteilen geschlafen haben, scheint es nun Handlungbedarf zu geben. Eine von vielen Fragen ist doch die nach der Qualität von Genzyme!? Ist genzyme genauso eine Rakete wie geltex? Wo liegen die Synergieeffekte, welchen Schub bedeutet die Aktion für genzyme, denn wenn wir nichts unternehmen gehört uns plötzlich nicht mehr ein ganz schönes stück von geltex, sondern nur noch ein kleines bisschen von genzyme?

Also was für ne story steckt hinter dem deal, wo ist der Haken? Wenn jemand was weiss von euch, schreibts doch einfach mal rein hier ins board.

vielen dank erstmal

k. e.

[gholzbauer]

GENZ ist der älteste Biotech-Posten in meinem Depot. Performance O.K., aber nicht überragend. Mkp. GENZ 5 Mrd. $, GELX jetzt 1 Mrd. $, d.h. wenn GELX sich vom jetzigen Niveau aus auf 2 Mrd. $ verdoppeln würde, reicht es kombiniert mit GENZ nur für einen Anstieg von 6 Mrd. auf 7 Mrd., falls GENZ alleine stagnieren würde. GENZ ist aber einer der billigsten Biotech-Werte ("trailing" KGV ca. 25 bei 20-30% jährl. Wachstum) und hat eine Vielzahl von Produkten in Entwicklung.
Ich glaube, der Markt wird die vollständige Kontrolle über Renagel für GENZ honorieren (bisher 50/50 JV) und ein höheres KGV (vielleicht 35 ?) bewilligen.
http://www.siliconinvestor.com/research/chart.gsp?s=GENZ&tim…

[Edilo]

Was raten die Experten? Geltex halten oder verkaufen?

[gholzbauer]

GENZ hat sich bereits auf über 66$ erholt. 66$x0,7272=48$ für GELX. Bei einem GENZ-Kurs von über 65,5 $ ist zumindest der Umtausch ratsam, wenn man davon ausgeht, daß GENZ nicht zurückfällt.

Vom 12.9.00:

Shares of Genzyme (GENZ: news, msgs) climbed $1.88 to $59.56. Genzyme had declined sharply Monday after the Cambridge, Mass.-based biotech said it would acquire GelTex Pharmaceuticals (GELX: news, msgs) for $1 billion in cash and stock. Genzyme said Monday that the acquisition is expected to dilute earnings in the near term.

Investors` concerns about earnings contributed to the decline in Genzyme`s stock Monday. On Tuesday, some analysts came to the deal`s defense, saying it will be beneficial for Genzyme.

In a research note, PaineWebber analyst Elise Wang said GelTex already has two promising products. GelTex sells Renagel for the treatment of patients undergoing kidney dialysis, and WelChol, a cholesterol-lowering drug.

"We view this transaction favorably, as GelTex has successfully gained FDA approval for two products and continues to make solid progress on its pipeline," Wang wrote in her research note.

Shares of GelTex were up 75 cents to $44.

Quelle:http://cbs.marketwatch.com/archive/20000912/news/current/btk…

[gholzbauer]

"66$x0,7272=48$ für GELX" sollte es im vorherigen Posting heißen.

[gholzbauer]

Verd...., warum wird der Text dauernd verstümmelt?
Nochmal:
66$ x 0,7272 (Umtauschverhältnis) = 48$ für GELX

[kostolanys erben]

Liebe Geltexler,

geschickte und (sehr) liquide besitzer von geltexanteilen kaufen jetzt genzymepapiere; sie erreichen damit, daß sowohl der kurs von geltex als auch von genzyme steigt. genau das passiert gerade.

es stellt sich die frage ob es sich lohnt den trend bis zum schluss auszureizen. all zu viel wird geltex nicht mehr performen. man bedenke, daß der kursanstieg der geltexaktie durch regelmäßige käufe von genzyme Inc. verursacht wurde. welcher anteil von geltex gehört bereits jetzt schon der firma genzyme?

der rasante kursverfall der genzymeaktie kurz vor der bekanntgabe der übernahme von geltex kam durch insiderverkäufe zustande? wer hat verkauft und warum?

für denkanstösse und hinweise auf mögliche fehlinterpretationen unsererseits sind wir dankbar.

grüße von

k.e.

[gholzbauer]

TEST (mein Browser spinnt)

[gholzbauer]

Welchol(TM) (Colesevelam HCl) Now Available for Treatment Of Elevated Cholesterol New National Survey Shows Cholesterol Patients Are Concerned About Drug Absorption and Would Prefer a Non-Absorbed Option for Cholesterol Lowering
PARSIPPANY, N.J., Sep 19, 2000 /PRNewswire via COMTEX/ -- Sankyo Pharma, the commercial partner of GelTex Pharmaceuticals, today announced that WelChol(TM) (colesevelam HCl) is now available by prescription in pharmacies nationwide. WelChol effectively lowers LDL cholesterol (or "bad cholesterol") and is also the only lipid-lowering agent that is FDA-approved for combination use with a statin. Administered alone or in combination with a statin, WelChol is indicated as adjunctive therapy to diet and exercise for the reduction of elevated LDL cholesterol in patients with primary hypercholesterolemia (Fredrickson Type IIa) when diet and exercise alone are not adequate.

Unlike the most frequently prescribed cholesterol-lowering drugs, WelChol is nonsystemic, which means it is not absorbed into the bloodstream and does not travel throughout the body. "Patients with elevated cholesterol may benefit from having this new non-absorbed option because they can avoid systemic side effects that might accompany absorbed cholesterol-lowering drugs," said Michael Davidson, MD, assistant professor, department of medicine, Rush Presbyterian-St. Luke`s Medical Center, Chicago, and president, Chicago Center for Clinical Research. "A non-absorbed drug can be especially useful in patients who are already taking several medications and in people who will remain on therapy for many years."

WelChol has a favorable safety profile. The most common side effects (>5%) are gas, constipation, infection, upset stomach and headache.

WelChol also has a favorable drug-drug interaction profile. In human drug interaction studies, WelChol had no significant effect on the absorption of digoxin, lovastatin, metoprolol, quinidine, valproic acid or warfarin, some of which are known to interact with other lipid-lowering agents. Although it did decrease the absorption of sustained-release verapamil, the clinical significance of this was unknown due to the variable bioavailability of verapamil. WelChol has not been studied with all drugs, therefore like all drugs, patients should always tell their health care provider about all the medicines and supplements they are taking.

The need to control elevated cholesterol levels is gaining attention as more information is learned about the risks of high cholesterol levels. A recent study published in the Journal of the American Medical Association underscored the urgency of controlling cholesterol in young people, finding that even men under the age of 40 with elevated cholesterol run an increased risk of heart disease and premature death(1).

But despite the health risks associated with high cholesterol, a new national survey shows that people have concerns about taking drugs to control it. Sponsored by Citizens for Public Action on Blood Pressure and Cholesterol with an educational grant from Sankyo Pharma, the survey polled 500 adults with elevated cholesterol levels. Specifically, the survey found that 64% of respondents avoid taking drugs because they are concerned about side effects, and 79% are concerned about increasing the amount of drugs absorbed into the body(2).

The survey also showed that patients do not understand how currently available drugs work in the body. According to the survey, 73% did not know whether the drug they were taking was absorbed or non-absorbed(3) but 97% said they would be likely to ask their doctor about a non-absorbed option(4).

"The survey showed that people know it`s important to keep their cholesterol low, but they are also interested in doing it with the lowest drug dose possible," said Gerald Wilson, director of Citizens for Public Action on Blood Pressure and Cholesterol. "We hope that as more treatment options become available, people with high cholesterol will find a therapy they`re comfortable with."

The survey revealed that despite the existence of cholesterol guidelines published by the National Cholesterol Education Program (NCEP), only 54% of those surveyed knew their cholesterol level goals(5). Another study published this year in the Archives of Internal Medicine, called the Lipid Treatment Assessment Project (L-TAP), showed that only 38% of patients with elevated cholesterol levels receiving cholesterol-lowering therapy achieved their NCEP LDL cholesterol target levels. The rate is even lower for patients with established coronary heart disease -- 18%(6).

"L-TAP demonstrated a need for a treatment that could work with existing cholesterol medication to help patients who are finding it very difficult to meet their target levels," said William L. Bailey, Pharm.D., director, medical and scientific affairs, Sankyo Pharma. "We are enthusiastic about the results of clinical trials, showing that using WelChol is safe and effective in lowering LDL cholesterol. The fact that substantial additional cholesterol lowering was achieved with WelChol, in combination with a statin, should significantly aid cholesterol-management efforts."

Clinical trials have demonstrated that co-administration of WelChol and statin drugs (Lipitor(R)/atorvastatin, Mevacor(R)/lovastatin and Zocor(R)/simvastatin) can lower LDL cholesterol levels more dramatically than using either therapy alone. In a clinical study, WelChol 3.8 g per day combined with Lipitor (R) (atorvastatin) 10 mg per day, which is the most frequently prescribed lipid-lowering agent in the U.S.(7), resulted in a 48% average reduction in LDL cholesterol. The study demonstrated that patients taking this combination achieved LDL-cholesterol reductions that were not statistically significantly different from taking 80 mg of Lipitor (which is 8 times the most commonly prescribed Lipitor dose)(8).

"Having an effective, safe option, such as WelChol, that can be added to statins, may greatly improve patients` success rates in meeting their cholesterol target levels," said Peter H. Jones, MD, associate professor of medicine, section of atherosclerosis and lipid research, Baylor College of Medicine. "And it can also be used alone as an important alternative for patients who are unable to tolerate statin therapy."

A recent study published in the Archives of Internal Medicine concluded that used alone, WelChol is effective in lowering LDL (the "bad" cholesterol) by up to 19% while increasing HDL or "good" cholesterol(9). Other studies have demonstrated that WelChol lowers LDL cholesterol by 15%-18%.

Cholesterol is the principal building block for bile acids, which help us digest food. WelChol works by binding to bile acids in the intestine and taking those bile acids with it as it leaves the body. The body responds naturally by drawing cholesterol from the bloodstream to replenish the supply, resulting in an overall lowering of cholesterol in the bloodstream. WelChol is available as 625 mg solid tablets. The recommended dose is 6 tablets taken once per day or 3 tablets taken twice per day with meals and a liquid. WelChol should not be taken by patients who have a bowel obstruction. As with all cholesterol-lowering agents, serum total-C, LDL-C and triglyceride levels should be determined periodically, based on NCEP guidelines, to confirm favorable initial and long-term responses.

About the Survey

Roper Starch Worldwide conducted telephone interviews with 500 adults 20 years of age and older with elevated cholesterol levels. The margin of sampling error is +/- 4 percentage points. Responses were weighted by age within sex and by region to ensure accurate representation of the study universe. All interviewing was conducted during August 2000.

About Sankyo Pharma

Sankyo Pharma is dedicated to developing and marketing innovative pharmaceuticals for the US market. Sankyo Pharma has operations in New York and New Jersey with a Research Institute in California. A national sales force of 350 people, including a dedicated managed care sales force promotes Sankyo Pharma products. Sankyo Pharma also co-promotes Accupril(R) (quinapril), an ACE inhibitor therapy for the treatment of hypertension.

Sankyo Pharma`s parent company, Sankyo Co., Ltd. of Tokyo, is a global innovator and a primary source of new therapeutic agents including drugs for hypertension and cardiovascular disease. Sankyo played an important role in establishing the HMG-CoA reductase inhibitor (or "statin") class of lipid-lowering agents. Sankyo originated the statin class in 1971 with the discovery of mevastatin, although mevastatin was not commercialized. Sankyo also co-discovered lovastatin, the first statin therapy to be marketed. It discovered, co-developed and manufactures pravastatin. Sankyo independently markets pravastatin throughout the world and through its licensee, Bristol-Myers Squibb. Pravastatin is marketed as Pravachol(R) in the United States. Sankyo is also the originator of cefpodoxime proxetil, a cephalosporin antibiotic sold in 57 countries around the world. It is sold by Pharmacia as Vantin(R) in the United States, and by Aventis in Europe.

Please see package insert for full prescribing information.

Lipitor(R) is a registered trademark of Pfizer Inc; Mevacor(R) and Zocor(R) are registered trademarks of Merck & Co., Inc.; Pravachol is a registered trademark of Bristol-Myers Squibb.


References
(1) Stamler J, et al. Relationship of Baseline Serum Cholesterol Levels in
3 Large Cohorts of Younger Men to Long-term Coronary, Cardiovascular
and All-Cause Mortality and to Longevity. JAMA. 2000; 284:311-318.
(2) Roper Starch Worldwide/Cholesterol Concerns: Apprehension and
Apathy/August 2000. p. 17.
(3) Roper Starch, p. 20.
(4) Roper Starch, p. 22.
(5) Roper Starch, p. 16.
(6) Pearson, T et al. The Lipid Treatment Assessment Project (L-TAP): A
Multicenter Survey to Evaluate the Percentages of Dyslipidemic
Patients Receiving Lipid-Lowering Therapy and Achieving Low-Density
Lipoprotein Cholesterol Goals. Archives of Internal Medicine. 2000;
160:459-467.
(7) IMS National Prescription Audit Basic Data Report. January-March 2000.
(8) Data on file.
(9) Davidson, Michael et al. Colesevelam Hydrochloride (Cholestagel): A
New Potent Bile Acid Sequestrant Associated with a Low Incidence of
Gastrointestinal Side Effects. Archives of Internal Medicine. 1999;
159:1893-1900.



Source: Sankyo Pharma

[gholzbauer]

@kostolanys erben
????

Es ist ein ganz normaler Vorgang, daß der Kurs des Übernehmers unter Druck kommt (dilution of earnings), während der Kurs des übernommenen Unternehmens steigt.
Der Anstieg danach bei GENZ ist nicht "(liquiden Geltex-Aktionären)" zuzuschreiben, hier haben ein paar Analysten und der Markt nur bemerkt, daß der Deal für GENZ vorteilhaft ist.
Ob es (illegale) Insiderverkäufe gegeben hat, ist mir egal, die langfristigen Aussichten für GENZ sind jetzt eher besser denn schlechter, IMO. Welchol und Renagel sind sehr attraktive Produkte, die zusammen mit der GELX-Pipeline günstig übernommen werden konnten. GENZ hätte im letzten Herbst schon diese Übernahme versuchen sollen, als GELX unter 15$ notierten. Damals war GENZ allerdings durch die dann fehlgeschlagene CEGE-Übernahme anderweitig beschäftigt.
Letztlich ist es für mich vorteilhaft, daß die Übernahme erst jetzt kommt, denn damals hätte ich für meine GELX-Aktien ein deutlich niedrigeres Angebot bekommen.

EmmEffGee, gholzbauer

[Edilo]

seit ein paar Tagen tritt der Kurs auf der Stelle.
Wer kann Infos geben?

[gholzbauer]

Machst du dir nie die Mühe, die letzten paar Postings durchzulesen, bevor du eine Frage stellst?
Warum der Kurs auf der Stelle steht, geht aus obigen Texten hervor.

[hgw]

Wer weiß was neues von Geltex?
Ist der Kauf nun perfekt und wann wird er ausgeführt.
Über Anworten würde ich mich freuen

hgw

[gholzbauer]

Läuft alles wie geplant, Umtausch der Aktien muß spätestens im Januar erfolgen, wenn die GELX-Aktionäre zustimmen. GELX notieren übrigens unter dem Umtauschkurs von 0,7272x80$(<-aktueller GENZ-Kurs)=58$, GELX nur 52$. Allerdings weiß ich nicht, ob man einen Teil Cash (47.5$) nehmen muß oder ausschließlich GENZ-Aktien nehmen kann. Der aktuelle GELX-Kurs scheint die erste Möglichkeit einzupreisen.



Genzyme and GelTex Announce Filing of Registration Statement for Genzyme`s Acquisition of GelTex
CAMBRIDGE and WALTHAM, Mass., Nov 1, 2000 /PRNewswire via COMTEX/ -- Genzyme Corp. and GelTex Pharmaceuticals, Inc. (Nasdaq: GELX chart, msgs) today announced the filing of Genzyme`s registration statement with the Securities and Exchange Commission (SEC) for the acquisition of GelTex by Genzyme. The transaction was announced on September 11, 2000.

The companies expect the transaction to close in December or January, pending regulatory and GelTex shareholder approval. GelTex will then become a part of Genzyme General (Nasdaq: GENZ chart, msgs), a division of Genzyme Corp.

With the acquisition, Genzyme General will have access to two patent- protected, marketed products -- Renagel(R) brand sevelamer hydrochloride and WelChol(TM) brand colesevelam hydrochloride -- along with a significant pipeline of promising products and a proven and productive polymer technology development team. Renagel is a rapidly growing product used in the treatment of patients with end-stage renal disease undergoing hemodialysis. WelChol is a new cholesterol-lowering agent that was launched in September 2000 by Sankyo Pharma, Inc.

GelTex`s leading product in development is a toxin binder known as GT160- 246 for Clostridium difficile (C. difficile), which is a major cause of antibiotic-associated colitis, a condition common in hospitals and nursing homes. A Phase 1 trial of GT160-246 in normal volunteers was completed in August, and a Phase 2 clinical trial of the product is expected to begin later this year. In addition, GelTex has identified a family of polymers that inhibit pancreatic lipase, the key enzyme involved in fat digestion in the intestine. In pre-clinical studies, these compounds have shown they can inhibit lipase with a potency in the range of that of known inhibitors. They have also shown that they can significantly inhibit fat absorption.

GelTex`s polymer technology development team has produced two approved products and several promising product candidates within a short six-year timespan. Polymer technology has wide ranging applications, and the two polymers developed by GelTex to date have had a relatively quick development pathway and have proven to be very safe.

Genzyme General develops and markets therapeutic products and diagnostic products and services. Genzyme General has three therapeutic products on the market and a strong pipeline of products in development focused on the treatment of genetic disorders. Genzyme General is a division of the biotechnology company Genzyme Corporation.

GelTex develops and markets non-absorbed polymer drugs that bind and eliminate targeted substances within the gastrointestinal tract. In addition, GelTex is developing small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators.

[brinco]

hat jemand einen tip, was man machen soll?
habe schreiben von codi:
1. variante: barabfindung 47,50
2. umtausch 1 zu 0,7272 (wär ja nicht schlecht z.zt)
3. kombination aus 1 + 2

aber zusatz!: bei überzeichnung variante 1+2 hält sich gesellschaft das recht auf repartierung vor(auf "pro-rata-basis") vor. weiß jemand was das ist?
kann man damit zur vollständigen barabfindung (47,50) gezungen werden? - das wär ja wohl ein schlechtes geschäft!
kann man die aktien jetzt überhaupt noch verkaufen, um eine
erzwungene barabfindung zu vermeiden?

danke für infos

gruß von brinco

[gholzbauer]

Eine vollständige Barabfindung wird es nicht geben.
Repartierung hieße, daß man für einen von Genyme festgelegten Teil seiner Geltex-Aktien 47,5$ pro Stück bekommt, für den anderen Teil Genzyme-Aktien. Ich könnte mir vorstellen, daß GENZ eher bestrebt sein wird, soviel eigene Aktien und sowenig Bargeldwie möglich auszugeben, so daß der Aktienanteil der Transaktion gut über 50% betragen kann.